


Approccio diagnostico-terapeutico al paziente con NET pancreatico - imaging radiologico -

Luigi Funicelli

Luigi.funicelli@ieo.it

NET imaging features



Imaging findings of NETs are not necessarily specific to a particular group (I, II, III) and they seem to overlap one another

TC multifasica

Diagnosi/Staging

Follow-up

MDCT with multiphasic acquisitions still remains the best method to perform diagnosis, staging, surveillance and follow-up.

Table 1. CT diagnosis of NETs

Type of NET	Mean sensitivity	Mean specificity	Mean detection rate	Patients/studies	Ref.
NET disease	82 (77–85)	86 (71–85)		253/4	3–6
Pancreatic NET	82 (67–96)	96		119/2	10–11
Liver metastases			79 (73–94)	79/3	7–9
	84 (75–100)	92 (83–100)		342/5	3, 12–15
Extrahepatic abdominal soft tissue metastases	70 (60–100)	96 (87–100)		451/6	3, 12–15, 17
Bone metastases	61 (46–80)	99 (98–100)		337/3	3, 18,19
CT enteroclysis for small intestinal NETs	50	25		8/1	20
	85	97		219/1 ^a	21

Data in the literature on the sensitivity, specificity and detection rate for NET diagnosis by CT. Figures are percentages with ranges in parentheses unless indicated otherwise. ^a Out of 219 patients included in the study, there were 19 subjects with small intestinal NETs.

Original paper

Differentiation between non-hypervascular pancreatic neuroendocrine tumour and pancreatic ductal adenocarcinoma on dynamic computed tomography and non-enhanced magnetic resonance imaging

Kazuyoshi Ohki^{A,D,E,F}, Takao Igarashi^{A,C,D}, Hirokazu Ashida^D, Megumi Shiraishi^B, Yosuke Nozawa^F, Hiroya Ojiri^F

The Jikei University School of Medicine, Japan


Pol J Radiol 2019; 84: e153-e161

- Caratteristiche radiologiche comuni
 - Margini ben definiti
 - Ipervascolari in fase arteriosa
 - Iper o iso nella fase portale
 - Aree cistiche
 - Calcificazioni
 - Non dilatazione del dotto pancreatico principale

G1 o G2>>>G3 (NEC)



Homogeneous enhancing




heterogeneous enhancing

VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN Preceptorship

IEO
Istituto Europeo di Oncologia



- Caratteristiche non comuni
 - Margini mal definiti
 - Ipovascolare in arteriosa e portale
 - Dilatazione del dotto pancreatico principale



G1 o G2<<< G3 (NEC)

DDx. Adenocarcinoma duttale del pancreas

VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN Preceptorship

IEO
Istituto Europeo di Oncologia



- Caratteristiche comuni
 - Margini ben definiti
 - Ipervascolari in Arteriosa
 - iper o iso in fase venosa
 - Aspetto cistico
 - calcificazioni
- Caratteristiche non comuni
 - Margini mal definiti
 - Ipovascolari in Art e Portale
 - Dilatazione del dotto pancreatico

G1 o G2

G3

Ddx metastasi, milza
accessoria


Ddx Adenoca Pancreatico

FOLLOW-UP

Early arterial phase



Late arterial phase



VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN Preceptorship

IEO
Istituto Europeo di Oncologia

Early
Arterial
Phase



Late
Arterial
Phase




MR has a better performance(hepatospecific c.m. & DWI) detecting: brain & bone mets and pancreatic lesions (particularly for hypovascular ones).

Table 2. MRI diagnosis of NETs




Type of NET	Mean sensitivity	Mean specificity	Mean detection rate	Patients/studies	Ref.
Gastrinoma	70			122/1	28
Pancreatic NET	79 (54–100)	100	76 (61–95)	258/7	11, 29–34
Liver metastases	75 (70–80)	98		200/2	40, 41
Carcinomatosis			88 (81–91)	72/2	42, 43

Data in the literature on the sensitivity, specificity and detection rate for NET diagnosis by MRI. Figures are percentages with ranges in parentheses unless indicated otherwise.

Good detection rate for liver mets(MdC epatospecifico e DWI), brain & bone mets & pancreatic tumour (hypovascular).



The MR has a better performance(hepatospecific c.m. & DWI)
(hepatospecific c.m. & DWI)



REVIEW

Diagnostic Performance of Apparent Diffusion
Coefficient for Prediction of Grading of
Pancreatic Neuroendocrine Tumors

A Systematic Review and Meta-analysis


Rui Long Zong, MS,* Li Geng, MS,† Xiaohong Wang, MS,‡ and Daohai Xie, MD, PhD‡

- Mean ADC values
 - G1: 1283 [SD,0.27] $\mu\text{m}^2/\text{s}$
 - G2: 0892 [SD, 0.39] $10^{-3} \mu\text{m}^2/\text{s}$
 - G3 : 0733 [SD, 0.23] $10^{-3} \mu\text{m}^2/\text{s}$

VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN  **Preceptorship**


 **IEO**
Istituto Europeo di Oncologia



VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN  Preceptorship

 IEO
Istituto Europeo di Oncologia




FOLLOW-UP

“Short MRI follow-up protocol in the evaluation of hepatic metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NET)”

Z. Aleksander-Markuszcwska, L. Funicelli, V. Giannetta, R. Labruna, N. Fazio, M. Bellomi; 1Warsaw/PL, 2Milan/IT







BASELINE



FOLLOW-UP (+12 months)



BASELINE




FOLLOW-UP (+12 months)

VIII EDIZIONE
NEN PRECEPTORSHIP
**LA PRATICA CLINICA NELLE
NEOPLASIE NEUROENDOCRINE**

NEN  Preceptorship

 IEO
Istituto Europeo di Oncologia



GRAZIE